Lung Cancer: State of the Art
Resource Topics rightRail
Four courses of cisplatin or carboplatin plus etoposide remain standard first-line therapy. A plateau has been reached with chemotherapy regimens, and novel strategies are greatly needed to improve survival for patients with SCLC.
- Bardenklänge Vol.12 - Guitar?
- LUNG CANCER STATE OF THE ART: : PG11!
- Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents..
- Slaying Excel Dragons: A Beginners Guide to Conquering Excels Frustrations and Making Excel Fun;
National Center for Biotechnology Information , U. Didn't get the message?
Small-cell lung cancer: state of the art. - PubMed - NCBI
Add to My Bibliography. J Natl Cancer Inst Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Long-term benefit is observed in a phase III comparison of sequential vs. RTOG abstract Proc Am Soc Clin Oncol Is there a preferred combination chemotherapy regimen for metastatic non-small cell lung cancer? Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Small-cell lung cancer: state of the art.
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced nonsmall- cell lung cancer: A phase III randomized trial. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced nonsmall- cell lung cancer: A Southwest Oncology Group trial. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens.
LUNG CANCER STATE OF THE ART: 2017
Randomized phase III study of pemetrexed vs docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. Salgia R, Skarin AT: Molecular abnormalities in lung cancer. Novel targets for lung cancer therapy: Part I and part II.
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase in symptomatic patients with non—small cell lung cancer: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage smallcell lung cancer: Twice daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
Proton beam therapy in non-small cell lung cancer: state of the art
A randomized phase III study. Semin Oncol 21 2 suppl 6: Targeted therapy describes treatment strategies that focus on cell signaling and other biologic pathways involved in tumorigenesis. Several targeted agents have been introduced in clinical trials in NSCLC, the majority in advanced disease, and some phase III studies have already produced definitive results.
Currently, the minority of these new agents offer promise of improved outcomes and negative results are more common to be reported than positive ones. However, important lessons can be learned from this first generation of clinical trials that should be considered the first step of clinical research in this field. National Center for Biotechnology Information , U.
- Mémoires de Constant.
- Overview and State of the Art in the Management of Lung Cancer?